All Stories

  1. EP9158H: An Immunoinformatics-Designed mRNA Vaccine Encoding Multi-Epitope Antigens and Dual TLR Agonists for Tuberculosis Prevention
  2. HeptaTB Dx: a diagnostic model leveraging cuproptosis-ferroptosis crosstalk for distinguishing latent from active tuberculosis
  3. Tuberculosis Vaccines: Multidimensional Exploration and Breakthroughs from Innovative Design to Evaluation Systems
  4. Burden of 375 diseases and injuries, risk-attributable burden of 88 risk factors, and healthy life expectancy in 204 countries and territories, including 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study...
  5. Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990–2023: a systematic analysis for the Global Burden of Disease Study 2023
  6. Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023
  7. CP91110P: A Computationally Designed Multi-Epitope Vaccine Candidate for Tuberculosis via TLR-2/4 Synergistic Immunomodulation
  8. Evaluating H56:IC31 vaccine in tuberculosis recurrence prevention
  9. Diagnostic dilemmas and strain diversity in the MTBVAC phase 1b–2a trial in adults
  10. Application value of nucleic acid MALDI-TOF MS in mycobacterial species identification and drug resistance detection in Mycobacterium tuberculosis
  11. Development and Validation of Early Alert Model for Diabetes Mellitus–Tuberculosis Comorbidity
  12. Bibliometric analysis and knowledge mapping of diabetes mellitus combined with tuberculosis research: trends from 1995 to 2023
  13. Tuberculosis vaccines and therapeutic drug: challenges and future directions
  14. Decoding the WHO Global Tuberculosis Report 2024: A Critical Analysis of Global and Chinese Key Data
  15. Mendelian susceptibility to mycobacterial disease: a rare genetic disorder that demands attention
  16. Leveraging computer-aided design and artificial intelligence to develop a next-generation multi-epitope tuberculosis vaccine candidate
  17. Machine learning model based on SERPING1, C1QB, and C1QC: A novel diagnostic approach for latent tuberculosis infection
  18. Visualization analysis of research progress and trends in coexistence of lung cancer and pulmonary tuberculosis using bibliometrics
  19. WITHDRAWN: Physiological modeling and biomechanical insights of cytokine modulation in COVID-19 and pulmonary fibrosis through a multi-dimensional graph-based approach
  20. Revisiting Bacille Calmette‐Guérin revaccination strategies: timing of immunization, Mycobacterium tuberculosis and non‐tuberculous mycobacteria infections, strain potency and standardization of randomized controlled trials
  21. Construction of novel multi-epitope-based diagnostic biomarker HP16118P and its application in the differential diagnosis of Mycobacterium tuberculosis latent infection
  22. Editorial: Immunological aspects of emerging and re-emerging zoonoses
  23. Impact of diabetes mellitus on tuberculosis prevention, diagnosis, and treatment from an immunologic perspective
  24. Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control
  25. Application of artificial intelligence in diagnosis of pulmonary tuberculosis
  26. Harnessing bioinformatics for the development of a promising multi-epitope vaccine against tuberculosis: The ZL9810L vaccine
  27. Development and Evaluation of a Promising Biomarker for Diagnosis of Latent and Active Tuberculosis Infection
  28. Mycobacterium tuberculosis: immune response, biomarkers, and therapeutic intervention
  29. Research Advances of Tuberculosis Vaccine and its Implication on COVID-19
  30. From immunology to artificial intelligence: revolutionizing latent tuberculosis infection diagnosis with machine learning
  31. Design and development of a multi‐epitope vaccine for the prevention of latent tuberculosis infection
  32. A comprehensive approach to developing a multi-epitope vaccine against Mycobacterium tuberculosis: from in silico design to in vitro immunization evaluation
  33. Building a model for the differential diagnosis of non-tuberculous mycobacterial lung disease and pulmonary tuberculosis: A case-control study based on immunological and radiological features
  34. Exploring BCG vaccination as a novel approach to prevent recurrent herpes labialis
  35. Immunotherapy and biomarkers in patients with lung cancer with tuberculosis: Recent advances and future Directions
  36. Spatial-temporal patterns and influencing factors for pulmonary tuberculosis transmission in China: an analysis based on 15 years of surveillance data
  37. Next-Generation TB Vaccines: Progress, Challenges, and Prospects
  38. LTBI-negative close contacts of tuberculosis are more likely to develop the disease: enlightenment and lessons from a cluster outbreak
  39. Verapamil Regulates the Macrophage Immunity to Mycobacterium tuberculosis through NF-κB Signaling
  40. Clinical characteristics of patients with non-tuberculous mycobacterial pulmonary disease: a seven-year follow-up study conducted in a certain tertiary hospital in Beijing
  41. Two issues should be noted when designing a clinical trial to evaluate BCG effects on COVID-19
  42. PP19128R, a Multiepitope Vaccine Designed to Prevent Latent Tuberculosis Infection, Induced Immune Responses In Silico and In Vitro Assays
  43. A Summary on Tuberculosis Vaccine Development—Where to Go?
  44. Preventive effects of Mycobacterium tuberculosis DNA vaccines on the mouse model with latent tuberculosis infection
  45. Editorial: Research advances of tuberculosis vaccine and its implication on COVID-19
  46. Corrigendum: Bioinformatics analysis and consistency verification of a novel tuberculosis vaccine candidate HP13138PB
  47. Developing a multiepitope vaccine for the prevention of SARS-CoV-2 and monkeypox virus co-infection: A reverse vaccinology analysis
  48. Research progress on specific and non-specific immune effects of BCG and the possibility of BCG protection against COVID-19
  49. Bioinformatics analysis and consistency verification of a novel tuberculosis vaccine candidate HP13138PB
  50. Immunoinformatic-Based Multi-Epitope Vaccine Design for Co-Infection of Mycobacterium tuberculosis and SARS-CoV-2
  51. Excluding Participants With Mycobacteria Infections From Clinical Trials: A Critical Consideration in Evaluating the Efficacy of BCG Against COVID-19
  52. RNA-seq Analysis of the BCG Vaccine in a Humanized Mouse Model
  53. Evaluation of the consistence between the results of immunoinformatics predictions and real-world animal experiments of a new tuberculosis vaccine MP3RT
  54. Effect of Lymphocyte Subsets on Bone Density in Senile Osteoporosis: A Retrospective Study
  55. CRISPR-Based Diagnostics: A Potential Tool to Address the Diagnostic Challenges of Tuberculosis
  56. Prediction of Th1 and Cytotoxic T Lymphocyte Epitopes of Mycobacterium tuberculosis and Evaluation of Their Potential in the Diagnosis of Tuberculosis in a Mouse Model and in Humans
  57. Endobronchial Valve Treatment of Tuberculous Cavities in Patients with Multidrug-Resistant Pulmonary Tuberculosis: A Randomized Clinical Study
  58. The Natural Effect of BCG Vaccination on COVID-19: The Debate Continues
  59. BCG Vaccination: A potential tool against COVID-19 and COVID-19-like Black Swan incidents
  60. In silico Analysis of Peptide-Based Biomarkers for the Diagnosis and Prevention of Latent Tuberculosis Infection
  61. Child hepatitis of unknown origin may be due to insufficient understanding of adenovirus pathogenicity
  62. Cellular Immunity of Patients with Tuberculosis Combined with Diabetes
  63. SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies
  64. The Potential Roles of BCG Vaccine in the Prevention or Treatment of COVID-19
  65. Impact of Diabetes Mellitus on the Immunity of Tuberculosis Patients: A Retrospective, Cross-Sectional Study
  66. Clinical Efficacy of a Combination of Thymopentin and Antituberculosis Drugs in Treating Drug-Resistant Pulmonary Tuberculosis: Meta Analysis
  67. Advances in Key Drug Target Identification and New Drug Development for Tuberculosis
  68. Peptide-Based Vaccines for Tuberculosis
  69. The Research Progress in Immunotherapy of Tuberculosis
  70. Differential Diagnosis of Latent Tuberculosis Infection and Active Tuberculosis: A Key to a Successful Tuberculosis Control Strategy
  71. A peptide-based vaccine ACP derived from antigens of Mycobacterium tuberculosis induced Th1 response but failed to enhance the protective efficacy of BCG in mice
  72. Is the tuberculosis vaccine BCG an alternative weapon for developing countries to defeat COVID-19?
  73. Experience and Lessons of Tuberculosis Prevention and Control During COVID-19 Pandemic in Clinic
  74. COVID-19 pandemic: SARS-CoV-2 specific vaccines and challenges, protection via BCG trained immunity, and clinical trials
  75. Comparative study on the antituberculous effect and mechanism of the traditional Chinese medicines NiuBeiXiaoHe extract and JieHeWan
  76. Tuberculosis vaccine BCG: the magical effect of the old vaccine in the fight against the COVID-19 pandemic
  77. Prediction and analyses of HLA‐II restricted Mycobacterium tuberculosis CD4 + T cell epitopes in the Chinese population
  78. Peptides-Based Vaccine MP3RT Induced Protective Immunity Against Mycobacterium Tuberculosis Infection in a Humanized Mouse Model
  79. Exploratory development of PCR-fluorescent probes in rapid detection of mutations associated with extensively drug-resistant tuberculosis
  80. Chinese Traditional Medicine NiuBeiXiaoHe (NBXH) Extracts Have the Function of Antituberculosis and Immune Recovery in BALB/c Mice
  81. Will Mutations in the Spike Protein of SARS-CoV-2 Lead to the Failure of COVID-19 Vaccines?
  82. Dynamic Changes in Chest CT Images Over 167 Days in 11 Patients with COVID-19: A Case Series and Literature Review
  83. Effects of Mycobacterium vaccae vaccine in a mouse model of tuberculosis: protective action and differentially expressed genes
  84. Mannose-binding lectin 2 gene polymorphisms and their association with tuberculosis in a Chinese population
  85. Macrophages enhance mesenchymal stem cell osteogenesis via down-regulation of reactive oxygen species
  86. Animal Models of Tuberculosis Vaccine Research: An Important Component in the Fight against Tuberculosis
  87. Immunogenicity and Therapeutic Effects of Latency-Associated Genes in a Mycobacterium Tuberculosis Reactivation Mouse Model
  88. The current status, challenges, and future developments of new tuberculosis vaccines
  89. Th1 epitope peptides induce protective immunity against Rickettsia rickettsii infection in C3H/HeN mice
  90. An alert of Mycobacterium tuberculosis infection of rhesus macaques in a wild zoo in China
  91. Enhanced Expression of T-Cell Immunoglobulin and Mucin Domain Protein 3 in Endothelial Cells Facilitates Intracellular Killing ofRickettsia heilongjiangensis
  92. Chloroform-Methanol Residue of Coxiella burnetii Markedly Potentiated the Specific Immunoprotection Elicited by a Recombinant Protein Fragment rOmpB-4 Derived from Outer Membrane Protein B of Rickettsia rickettsii in C3H/HeN Mice
  93. Rickettsia rickettsiiouter membrane protein YbgF induces protective immunity in C3H/HeN mice
  94. Enhanced protection against Rickettsia rickettsii infection in C3H/HeN mice by immunization with a combination of a recombinant adhesin rAdr2 and a protein fragment rOmpB-4 derived from outer membrane protein B
  95. Serological characterization of surface-exposed proteins of Coxiella burnetii
  96. Protective immunity against Rickettsia heilongjiangensis in a C3H/HeN mouse model mediated by outer membrane protein B-pulsed dendritic cells
  97. Genomic and comparative genomic analyses of Rickettsia heilongjiangensis provide insight into its evolution and pathogenesis
  98. Identification of Novel Surface-Exposed Proteins of Rickettsia rickettsii by Affinity Purification and Proteomics
  99. Microarray of surface-exposed proteins of rickettsia heilongjiangensisfor serodiagnosis of Far-eastern spotted fever
  100. Surface protein Adr2 of Rickettsia rickettsii induced protective immunity against Rocky Mountain spotted fever in C3H/HeN mice
  101. Exploratory Study on Th1 Epitope-Induced Protective Immunity against Coxiella burnetii Infection
  102. Recombinant protein YbgF induces protective immunity against Rickettsia heilongjiangensis infection in C3H/HeN mice
  103. Proteome Analysis and Serological Characterization of Surface-Exposed Proteins of Rickettsia heilongjiangensis